Navigation Links
Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
Date:11/21/2007

SAN DIEGO, Nov. 21 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that it will present at the 19th Annual Piper Jaffray Healthcare Conference on Tuesday, November 27, 2007, at 9:00 a.m. EST (6:00 a.m. PST). The conference is being held at the Pierre Hotel in New York.

Steve Worland, Ph.D., President and Chief Executive Officer of Anadys Pharmaceuticals, Inc., will present an overview of Anadys and its two development-stage product candidates, ANA598 and ANA773.

The presentation will be simultaneously webcast and can be accessed on the Investor Relations page of the Company's website at http://www.anadyspharma.com. Listeners are encouraged to visit the website approximately five minutes prior to the corporate presentation to download or install any necessary software. A replay of the presentation will be available approximately one hour after the live webcast concludes and will be available through December 11, 2007.

About Anadys

Anadys Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology. The Company is developing ANA598, a small-molecule, non-nucleoside inhibitor of the NS5B polymerase for the treatment of hepatitis C virus (HCV) infection and ANA773, an oral TLR7 agonist prodrug for cancer.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to Anadys' strategy, development programs, and ability to develop novel small molecule medic
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
2. Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
3. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
4. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
5. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
9. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
10. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
11. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2008)...Newswire-FirstCall/ -- Cell Therapeutics, Inc.,(CT...sent at three upcoming,investor conferences. The c...um in San Francisco in October, the 19th Annual Op... Annual Acumen BioFin Rodman & Renshaw,Healthcare ...he presentations will be webcast live with slides,...
(Date:10/10/2008)...Newswire-FirstCall/ -- Cell Therapeutics, Inc.,(CT... Company intends to,request a hearing with the NAS... for regaining compliance with NASDAQ Marketplace ...t value of listed securities of $50 million.,CTI r...AQ Stock Market LLC,on October 7, 2008 indicating ...
(Date:10/10/2008)... academia and industry reveal powerful effects of,... mammalian cell culture leading to a si...olo., Oct. 10 /- A recently published... & Developmental Biology,revealed that recombinant....Lacromin.com ) is a strong growth factor for prom...
(Date:10/10/2008)...10 /- Boston Scientific,Cor...ived approval from the,U.S. Food and Drug Administ...(R) Liberte(R) Paclitaxel-Eluting Coronary Stent S...te stent early next month in the United,States, fo...S(R),Expresss2(TM) Atom(TM) Paclitaxel-Eluting Cor...
Breaking Biology Technology:Cell Therapeutics, Inc. (CTI) to Present at Three Upcoming Investor Conferences 2Cell Therapeutics to Request a Hearing With NASDAQ Following Receipt of Staff Determination Letter 2Cell Therapeutics to Request a Hearing With NASDAQ Following Receipt of Staff Determination Letter 3New Study Finds Growth Factor Boosts Productivity in Mammalian Cell Culture 2Video: Boston Scientific Announces FDA Approval of Second-Generation TAXUS(R) Liberte(R) Drug-Eluting Stent 2Video: Boston Scientific Announces FDA Approval of Second-Generation TAXUS(R) Liberte(R) Drug-Eluting Stent 3
...he business section of Sunday,s San Jose Mercury N...ff 35% ." , ,After several quarters of increasing ...illion into new businesses last quarter, down a th...ding to the MoneyTree Survey conducted by Pricewat...National Venture Capital Association. While a 35% ...
...dison, Wis. Governor Jim Doyle announced today o...r the state to maintain its leadership in the fiel...l research. The governor said that almost $750 mil...eral years, and he outlined a series of investment...ry on the UW-Madison campus. , Read the latest...
...he other day I went to a lecture on angel investin...ience raised his hand. He wanted to know whether t...s from Fond du Lac to Green Bay had enough entrep...nvestors. , ,When I heard this, I realized that th...nsins perception of itself. A number of Wisconsin-...
...or years, our firm has been touting the Bureau of ...oyees will leave the workforce for every new one e...e of ten million employees. , ,In an election cycl...ff-shoring is becoming de rigueur, these numbers s...st common arguments I hear refuting BLS statistics...
Other Biology Technology:Start-ups grow up 2Start-ups grow up 3Wisconsins governor unveils $750 million investment for stem cell and health research 2Wisconsin entrepreneurs need to self-promote like coastal rivals 2Wisconsin entrepreneurs need to self-promote like coastal rivals 3Wisconsin entrepreneurs need to self-promote like coastal rivals 4Wisconsin entrepreneurs need to self-promote like coastal rivals 5Wisconsin entrepreneurs need to self-promote like coastal rivals 6Talent shortage? Cmon. 2
(Date:10/10/2008)... in German . , DNA, the molecule that acts as...f life, is highly resistant against alteration by ... for its photostability presents some puzzling pro... four chemical bases that make up the DNA molecule... showing that DNA strands differ in their light se...
(Date:10/9/2008).... 9 /PRNewswire-FirstCall/ -- Synaptics(R),Incorpo...an interface,solutions for mobile computing, commu...day that it will report financial results for the ...23, 2008 after the close of market. The,company wi...ts and,investors at 2:00 p.m. PT (5:00 p.m. ET) du...
(Date:10/9/2008)...ed life,s ability to respond? Biodiversity in a Wa...f the journal, Science , illustrates that cross-d...ropical Research Institute in Panama clearly infor...region of rainforest and coral reefs, the tropics ...rming. Some disagree, arguing that tropical organi...
(Date:10/9/2008)...years, the number of patients with compromised imm...tients such as these require a unique set of healt...thing from the etiology and degree of immune suppr...tus. A new text from ASM Press, Diagnostic Microbi...ide range of approaches and challenges to infectio...
Breaking Biology News(10 mins):Can genetic information be controlled by light? 2Synaptics to Report First Quarter Results on October 23 2Smithsonian perspective: Biodiversity in a warmer world 2Text focuses on diagnosing infections in immunocompromised patients 2Threshold for bowel surgery may be too high warn experts 5076 1Threshold for bowel surgery may be too high warn experts 5076 2MAP Pharmaceuticals Initiates Phase 2a Clinical Trial of Combination Therapy in Adult Patients with Asthma 5073 1MAP Pharmaceuticals Initiates Phase 2a Clinical Trial of Combination Therapy in Adult Patients with Asthma 5073 2MAP Pharmaceuticals Initiates Phase 2a Clinical Trial of Combination Therapy in Adult Patients with Asthma 5073 3MAP Pharmaceuticals Initiates Phase 2a Clinical Trial of Combination Therapy in Adult Patients with Asthma 5073 4Anesiva Announces Upcoming Webcasts and Conference Participation 5068 1Anesiva Announces Upcoming Webcasts and Conference Participation 5068 2King Pharmaceuticals and Acura Pharmaceuticals Enter Agreement to Develop and Commercialize Immediate Release Pain Medicines Utilizing Acuras Aversion 5063 1King Pharmaceuticals and Acura Pharmaceuticals Enter Agreement to Develop and Commercialize Immediate Release Pain Medicines Utilizing Acuras Aversion 5063 2King Pharmaceuticals and Acura Pharmaceuticals Enter Agreement to Develop and Commercialize Immediate Release Pain Medicines Utilizing Acuras Aversion 5063 3King Pharmaceuticals and Acura Pharmaceuticals Enter Agreement to Develop and Commercialize Immediate Release Pain Medicines Utilizing Acuras Aversion 5063 4King Pharmaceuticals and Acura Pharmaceuticals Enter Agreement to Develop and Commercialize Immediate Release Pain Medicines Utilizing Acuras Aversion 5063 5King Pharmaceuticals and Acura Pharmaceuticals Enter Agreement to Develop and Commercialize Immediate Release Pain Medicines Utilizing Acuras Aversion 5063 6
...trospective study in the Canadian Medical Associat...ularly boys, are about twice as likely as the tota...m an injury. , Brison and colleagues collected and...ries to young children to determine rates, identif...ms and ranches. They found that children 1? years ...
...e compounds could be a key component for cheaper, ...a Richards in Chemistry & Industry magazine. ,...each year, of which nearly 2,700 die, according to...ut is unsuitable for most patients, and liver tumo...an Cancer Society estimates that 18,510 new cases ...
...ers have found that the neurotransmitter serotonin...promote lasting, quality sleep in an animal model ...ntral to the lives of most animals, the proper reg... , The findings are reported by Quan Yuan, Willia...nnsylvania, and appear in the June 6th issue of Cu...
...e lovers, beware. Each year 20 percent of the caca...o plant diseases, but even greater losses would oc...eases are the most important constraints to cacao ...d,s confectionary trades," said Randy Ploetz, plan..., Homestead, FL. Currently, 4 million metric tons ...
Other Biology News:
Lyophilized. Purity: ≥90% by electrophoresis. Reconstitute in 0.3% NaCl. Prepared from serum that has been shown by certified tests to be negative for HBsAg and for HIV and HCV antibodies.
Porcine Pulmonary Artery Endothelial Cells (PPAEC) (>500,000 cells)
PP2B-Abeta (C-20)
... intensely fluorescent and highly photostable Fluo...se in a variety of applications requiring probes t...otein- and other macromolecule-labeled microsphere...bind to non-target surfaces in some applications. ...
Biology Products: